Henry Gosebruch - AbbVie Executive Vice President Chief Strategy Officer
| 4AB Stock | EUR 159.44 2.56 1.63% |
President
Mr. Henry O. Gosebruch is Executive Vice President, Chief Strategy Officer of the Company. He worked for more than 20 years in the Mergers Acquisitions Group at J.P. Morgan Securities LLC, serving as Managing Director since 2007 and as CoHead of MA North America during 2015. Mr. Gosebruch joined AbbVie in 2015. since 2015.
| Age | 45 |
| Tenure | 9 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
Henry Gosebruch Latest Insider Activity
Tracking and analyzing the buying and selling activities of Henry Gosebruch against AbbVie stock is an integral part of due diligence when investing in AbbVie. Henry Gosebruch insider activity provides valuable insight into whether AbbVie is net buyers or sellers over its current business cycle. Note, AbbVie insiders must abide by specific rules, including filing SEC forms every time they buy or sell AbbVie'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Henry Gosebruch over two months ago Acquisition by Henry Gosebruch of 80000 shares of Neumora Therapeutics subject to Rule 16b-3 |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joshua Smiley | Eli Lilly and | 47 | |
| Jan Lundberg | Eli Lilly and | 62 | |
| Fionnuala Walsh | Eli Lilly and | 56 | |
| Derica Rice | Eli Lilly and | 51 | |
| Enrique Conterno | Eli Lilly and | 49 | |
| Maria Crowe | Eli Lilly and | 55 | |
| David Ricks | Eli Lilly and | 55 | |
| Alfonso Zulueta | Eli Lilly and | 53 | |
| Stephen Fry | Eli Lilly and | 50 | |
| Melissa Barnes | Eli Lilly and | 47 | |
| Michael Harrington | Eli Lilly and | 53 | |
| Leigh Pusey | Eli Lilly and | 60 | |
| Barton Peterson | Eli Lilly and | 57 | |
| Jeffrey Simmons | Eli Lilly and | 48 | |
| Susan Mahony | Eli Lilly and | 51 | |
| Darren Carroll | Eli Lilly and | N/A | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Vice President Controller | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President CFO | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Senior Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, CEO | ||
| Brian Durkin, Vice President Controller | ||
| Thomas Hurwich, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Senior Vice President - Human Resources | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
| Roy Roberts, Independent Director | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 331.38 B | |||
| Shares Outstanding | 1.77 B | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 71.51 % | |||
| Price To Earning | 22.27 X | |||
| Price To Book | 18.07 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |